Published by Pinnacle Pulse, maker of a self-tracking app. We have no affiliate or sales relationship with any peptide seller. Editorial policy →

Epitalon: what the research shows, and what it doesn’t

By Pinnacle Pulse Editorial Team · Status as of 16 October 2026 · Next scheduled update: 14 January 2027

Short answer: Epitalon is a four-amino-acid peptide developed in St. Petersburg as a synthetic stand-in for a pineal gland extract. Lab studies report that it switches on telomerase in cells, and mouse studies report mixed effects on aging. Controlled human trials are essentially missing. In 2026 FDA staff concluded there was no clinical evidence of its safety in humans.

What epitalon is

Epitalon, also spelled epithalon or epithalone, is Ala-Glu-Asp-Gly, four amino acids long. It traces back to epithalamin, a preparation extracted from calf pineal glands. Researchers at the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson, designed the short synthetic peptide from the amino-acid makeup of that extract.

That origin story causes a common mix-up. Many of the human results quoted for epitalon were actually obtained with epithalamin, the extract, which is a different and much less defined product. A 2026 narrative review by US clinicians in the International Journal of Molecular Sciences stresses the point and treats the extract studies separately.

What has been studied

Cells: the telomere claim

The finding that made epitalon famous is a three-page paper from 2003. Khavinson’s group added the peptide to cultures of human fetal fibroblasts, cells that normally lack active telomerase, and reported that the enzyme switched on and telomeres lengthened. The authors suggested this could mean prolonging the life span “of the whole organism”. That is a large step from a dish of cells, and the paper doesn’t take it experimentally.

Mice: lifespan and tumours

The animal work largely comes from the same circle of researchers in St. Petersburg. The most cited study, in Biogerontology in 2003, injected female mice with epitalon for a few days each month from three months of age until death, 54 mice per group. Average lifespan didn’t change. The longest-lived tenth of the treated mice lived about 13 percent longer than their counterparts, and leukemia was less common, while total tumour incidence was the same.

FDA reviewed this body of work in 2026 and noted its limits: one fixed dose, female mice only, short intermittent exposure, and no standard two-year cancer study.

People

There is very little. A 2002 paper from the St. Petersburg institute described epitalon in patients with retinitis pigmentosa, an inherited eye disease, and reported a “positive clinical effect in 90% of the cases”. The abstract gives no information on controls. The often-cited study of 266 elderly people followed for six to eight years used epithalamin and thymalin, the extracts, not epitalon.

A PubMed search on 16 October 2026 for epitalon limited to clinical trials returned one record. The 2026 review sums up: epitalon is “biologically active but clinically unproven”, with no adequately powered randomized trial and inadequate data on pharmacokinetics and long-term safety.

The FDA review

In July 2026 FDA’s Pharmacy Compounding Advisory Committee looked at epitalon, nominated for insomnia. The agency’s briefing document is the most thorough independent look at the evidence so far. Its staff found no studies in people with insomnia, only data on melatonin levels. They wrote that there are “no clinical data to support the safety” of epitalon in humans and flagged possible immune reactions when it is injected under the skin. They added that it “has the potential to be carcinogenic”. Their reasoning: epitalon is reported to activate telomerase and lengthen telomeres, “and longer telomeres are generally associated with increased risk for cancer”. Overall, staff concluded that the evidence weighed against allowing it in compounding. FDA hasn’t posted the committee’s vote. When we checked its meeting page on 16 October 2026, it listed briefing documents, questions and slides, but no minutes.

What the research does not show

It doesn't show that epitalon slows aging or extends life in people. No human study has tested that.

It doesn’t show that the telomere effect is good news. A cell that keeps lengthening its telomeres is one of the features of cancer, which is exactly FDA’s concern.

It doesn’t show safety. There are no adequate pharmacokinetic or long-term data in humans.

And it largely hasn’t been replicated. Most of the published work comes from one research network that developed the peptide.

Status as of 16 October 2026. EU and US: not an authorized medicine (no entry in EMA’s medicines data or in Drugs@FDA). FDA staff advised against adding epitalon to the list of substances usable in 503A compounding (briefing, July 2026); FDA also lists it among withdrawn compounding nominations with possible safety risks. WADA: the 2027 Prohibited List does not name epitalon. Class S0 covers any pharmacological substance that isn’t addressed elsewhere on the List and has no approval for human therapeutic use, and it names peptides as an example.

FAQ

Is epitalon the same as epithalamin?

No. Epithalamin is an extract from animal pineal glands. Epitalon is a synthetic four-amino-acid peptide designed from it. Many human studies quoted for epitalon actually used epithalamin.

Does epitalon lengthen telomeres?

A 2003 cell-culture study reported that it activated telomerase and lengthened telomeres in human fetal fibroblasts. This has not been shown in people, and FDA staff noted that longer telomeres are generally associated with increased cancer risk.

What did FDA conclude about epitalon in 2026?

FDA staff found no studies in insomnia patients, no clinical data supporting safety in humans, a possible immune risk with injection and a potential carcinogenic risk. They concluded the evidence weighed against its use in compounding.

Sources

  • Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2. PMID 12937682
  • Anisimov VN, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. PMID 14501183
  • Khavinson V, et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-8. PMID 12195242
  • Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-40. PMID 14523363
  • Jain A, et al. Epitalon and epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence. Int J Mol Sci. 2026;27(19):8922. PMID 42884164
  • PubMed search “(epitalon OR epithalon) AND clinical trial[pt]”, run 16 October 2026 via NCBI E-utilities: 1 record.
  • FDA. Pharmacy Compounding Advisory Committee, 23-24 July 2026, briefing document on epitalon. fda.gov
  • FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). fda.gov
  • WADA. 2027 Prohibited List, class S0. wada-ama.org
  • EMA. Download medicine data: table of all medicines assessed by EMA (Excel), checked 16 October 2026. ema.europa.eu
  • FDA. Drugs@FDA, database of FDA-approved drugs, checked 16 October 2026. accessdata.fda.gov
  • WADA. 2027 Prohibited List, full text (PDF), checked 16 October 2026. wada-ama.org
  • FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee, checked 16 October 2026. fda.gov

Facts last checked: 16 October 2026.

About this article

Written by: the Pinnacle Pulse Editorial Team, the people who make the Pinnacle Pulse app. We work only from primary sources such as regulators, legal texts, trial registries and PubMed, and we remove claims we can’t check against one.

This article has not been reviewed by a physician. It is general information, not medical advice.

Spotted an error? Our editorial policy explains how to report it and how we correct mistakes.

Change log

  • 16 October 2026: First published.

From the makers of this site: Pinnacle Pulse is a neutral tracking app. We don’t sell or recommend any substance. About Pinnacle Pulse

This article is for general information only. It is not medical advice and does not recommend the use of any substance. Decisions about medicines belong with a qualified healthcare professional.